Medicamen Biotech Ltd (MEDICAMEQ) — shareholding pattern, promoter holding, financials and share price
About Medicamen Biotech Ltd (MEDICAMEQ)
Medicamen Biotech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as MEDICAMEQ and on the BSE under scrip code 531146. Its ISIN is INE646B01010.
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations [1]
Medicamen Biotech Limited (MBL) is a research-driven pharmaceutical company focusing on developing, manufacturing, and marketing finished dosage formulations globally.
MBL has a strong presence in over 40 countries and is a key player in the Indian oncology segment with its own sales force and branding team.
Listed peers in Pharmaceuticals: Astal Laboratories Ltd, Valiant Laboratories Ltd, Medico Remedies Ltd, Infinium Pharmachem Ltd, Trident Lifeline Ltd, Everest Organics Ltd.
Valuation & Returns
10 Jul 2026At ₹243.85 a share on 10 Jul 2026, Medicamen Biotech Ltd (MEDICAMEQ) was valued at a price-to-earnings ratio of 33.78x against an industry P/E of 36.41x and a price-to-book of 1.55x on a book value of ₹157.09 per share as of Mar 2025. Solomo computes return on equity of 4.6% and return on capital employed of 6.28% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 33.78x
- Industry P/E
- 36.41x
- P/B
- 1.55x
- EPS (TTM)
- ₹7.22
- Book value / share
- ₹157.09
- ROE
- 4.6%
- ROCE
- 6.28%
- ROA
- 3.29%
- Debt / equity
- 0.16x
- Dividend yield
- 0.41%
- EBITDA margin
- 11.48%
- 52-week range
- ₹216 – ₹454
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Medicamen Biotech Ltd (MEDICAMEQ) reported revenue of ₹198 crore, net profit of ₹10 crore and earnings per share of ₹7.11. That compares with revenue of ₹163 crore and net profit of ₹7 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹60.65 crore and net profit ₹4.45 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 115 | 141 | 179 | 163 | 198 |
| Net profit (₹ cr) | 15 | 15 | 9 | 7 | 10 |
| EPS (₹) | 12.2 | 11.73 | 8.6 | 5.59 | 7.11 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 9.43% | 5.24% | 9.47% | -9.35% |
| Profit growth | 39.22% | -5.08% | -14.10% | -30.87% |
| Stock price CAGR | 8% | -17% | -31% | -41% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 40.46% of Medicamen Biotech Ltd (MEDICAMEQ) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.07% and domestic institutional investors (DII) hold 0.4%. Market capitalisation was ₹331 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Pharmadanica A/S 9.88%, Veralogix Holdings(Pty) Ltd 4.42%, HUF 2.84%, Ginnerup Capital Aps 2.62%, Investor Education and Protection Fund (IEPF) 1.26%, Ritesh Kantilal Oswal 1.15%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 40.46% | - | 0.07% | 0.4% | 59.54% |
| Mar 2026 | 40.46% | - | 0.1% | - | 59.54% |
| Dec 2025 | 40.46% | - | 0.02% | 0.44% | 59.54% |
| Sep 2025 | 40.46% | - | 0.06% | 0.59% | 59.54% |
| Jun 2025 | 40.46% | - | 0% | 0.64% | 59.54% |
| Mar 2025 | 43.16% | - | 0.12% | 0.69% | 56.84% |
| Dec 2024 | 42.99% | - | 0.05% | 0.87% | 57.01% |
| Sep 2024 | 42.99% | - | 0.06% | 1.17% | 57.01% |